Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Cerebellar Ataxia|Friedreich Ataxia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| iPROACT-pilot | N/A |
Completed |
Inflammation|Type 2 Diabetes|Brain Diseases, Metabolic |
2025-02-25 |
|
| NCT01898884 | P1 |
Completed |
Friedreich Ataxia|Cerebellar Ataxia |
2015-06-18 |